Sign In
Buy FLXN
$25.10
-0.0069 (-0.0275%)
At Close: Jun 22, 2026
Edited Transcript of FLXN earnings conference call or presentation 12-Mar-20 8:30pm GMT
05:16am, Friday, 13'th Mar 2020
Q4 2019 Flexion Therapeutics Inc Earnings Call
Flexion Therapeutics, Inc. (FLXN) CEO Mike Clayman on Q4 2019 Results - Earnings Call Transcript
02:51am, Friday, 13'th Mar 2020
Flexion Therapeutics, Inc. (NASDAQ:FLXN) Q4 2019 Earnings Conference Call March 12, 2020 16:30 ET Company Participants Scott Young - VP Corporate Communications
Flexion Therapeutics (FLXN) Reports Q4 Loss, Tops Revenue Estimates
10:35pm, Thursday, 12'th Mar 2020
Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of 12.87% and 0.65%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Flexion Therapeutics (FLXN) Reports Q4 Loss, Tops Revenue Estimates
10:35pm, Thursday, 12'th Mar 2020
Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of 12.87% and 0.65%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Flexion Therapeutics: 4Q Earnings Snapshot
09:41pm, Thursday, 12'th Mar 2020
BURLINGTON, Mass. (AP) _ Flexion Therapeutics Inc. (FLXN) on Thursday reported a loss of $33.5 million in its fourth quarter. The Burlington, Massachusetts-based company said it had a loss of 88 cents
Flexion Therapeutics: 4Q Earnings Snapshot
09:40pm, Thursday, 12'th Mar 2020
BURLINGTON, Mass. (AP) _ Flexion Therapeutics Inc. (FLXN) on Thursday reported a loss of $33.5 million in its fourth quarter.
The Burlington, Massachusetts-based company said it had a loss of 88 cents
Flexion Therapeutics Reports Fourth-Quarter and Full-Year 2019 Financial Results
08:01pm, Thursday, 12'th Mar 2020
Flexion Therapeutics, Inc. (FLXN) today reported financial results and recent business highlights for the quarter and the full year ended December 31, 2019. “2019 marked an exciting period of growt
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
11:37am, Thursday, 12'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 11) * Bicycle Therapeutics PLC (NASDAQ: BCYC) (reacte
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
12:00am, Thursday, 12'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 11)
Bicycle Therapeutics...
Flexion Therapeutics Names Melissa Layman Chief Commercial Officer
08:30pm, Wednesday, 11'th Mar 2020
Flexion Therapeutics, Inc. (FLXN) today announced that Melissa Layman has been named Chief Commercial Officer (CCO). Ms. Layman joins Flexion with more than 25 years of commercial experience within t
Flexion Therapeutics Names Melissa Layman Chief Commercial Officer
08:30pm, Wednesday, 11'th Mar 2020
BURLINGTON, Mass., March 11, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Melissa Layman has been named Chief...
Flexion Therapeutics Names Melissa Layman Chief Commercial Officer
12:00am, Wednesday, 11'th Mar 2020Analysts Offer Insights on Healthcare Companies: Aurinia Pharmaceuticals (AUPH), BioCryst (BCRX) and Flexion Therapeutics (FLXN)
05:04pm, Monday, 09'th Mar 2020
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Aurinia Pharmaceuticals (AUPH), BioCryst (BCRX) and Flexion Therapeutics
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Aurinia Pharmaceuticals (
AUPH
–
Research Report
), BioCryst (
BCRX
–
Research Report
) and Flexion Therapeutics (
Artisan Partners Limited Partnership Invests $17.33 Million in Flexion Therapeutics Inc (NASDAQ:FLXN)
11:06am, Monday, 09'th Mar 2020
Artisan Partners Limited Partnership acquired a new position in shares of Flexion Therapeutics Inc (NASDAQ:FLXN) in the 4th quarter, according to the company in its most recent Form 13F filing with th
